What is the cause of hair loss and elevated eosinophils in an adult patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hair Loss and Elevated Eosinophils: Diagnostic Approach

Hair loss with elevated eosinophils most commonly indicates hypereosinophilic syndrome (HES) when other causes are excluded, requiring urgent evaluation for end-organ damage and immediate corticosteroid therapy if confirmed. 1

Initial Risk Stratification

The absolute eosinophil count (AEC) determines urgency and diagnostic approach:

  • Mild eosinophilia (0.5-1.5 × 10⁹/L): Most commonly caused by allergic disorders or medications in non-endemic areas, but helminth infections account for 19-80% in returning travelers 2
  • Moderate-to-severe eosinophilia (≥1.5 × 10⁹/L): Requires hematology referral if persisting >3 months after infectious causes excluded 2
  • Hypereosinophilia (≥1.5 × 10⁹/L): Demands immediate evaluation for end-organ damage regardless of symptoms 3, 2

Critical Red Flags Requiring Urgent Assessment

Evaluate immediately for life-threatening complications:

  • Cardiac involvement: Chest pain, dyspnea, heart failure symptoms, or arrhythmias suggest endomyocardial thrombosis/fibrosis, particularly with neoplastic HES variants 3, 2
  • Neurological symptoms: Altered mental status, focal deficits, or peripheral neuropathy indicate CNS/spinal cord involvement 3, 2
  • Pulmonary involvement: Persistent cough, wheezing, or infiltrates on imaging 3, 2

Systematic Diagnostic Workup

Step 1: Exclude Secondary Causes (Most Common)

Allergic disorders account for ~80% of secondary eosinophilia 3:

  • Atopic dermatitis, allergic rhinitis, asthma, drug reactions
  • Note: Alopecia areata (AA) patients with concurrent eosinophilia have 3.70 times higher odds of severe hair loss and increased nail abnormalities compared to AA without eosinophilia 4

Parasitic infections (second most common cause) 3:

  • Obtain detailed travel history: fresh water exposure in Africa/tropical regions, raw/undercooked meat consumption 2
  • Order 3 separate concentrated stool specimens for ova/parasites 2
  • Send Strongyloides and Schistosoma serology based on exposure history 2
  • Critical: Strongyloides can persist lifelong and cause fatal hyperinfection in immunocompromised patients 2

Medication reactions: Review all current and recent medications 5

Step 2: Assess for End-Organ Damage

Mandatory cardiac evaluation for AEC ≥1.5 × 10⁹/L 2:

  • ECG, cardiac troponin, NT-proBNP
  • Echocardiography if troponin elevated or cardiac symptoms present
  • Cardiac MRI to distinguish eosinophilic cardiac disease from other etiologies

Dermatologic assessment (directly relevant to hair loss):

  • Deep skin biopsy including fascia to document eosinophilic infiltration 2
  • Scalp biopsy showing dense perifollicular eosinophilic infiltration confirms HES-related alopecia 1

Additional organ systems 3, 2:

  • Pulmonary: Chest X-ray, pulmonary function tests if respiratory symptoms
  • GI: Endoscopy with biopsies if dysphagia, diarrhea, or abdominal pain
  • Neurologic: EMG and nerve biopsy if peripheral neuropathy suspected

Step 3: Rule Out Myeloproliferative/Lymphocytic Variants

If secondary causes excluded and hypereosinophilia persists 3:

  • Bone marrow biopsy with cytogenetics
  • Test for FIP1L1-PDGFRA fusion gene (responds to imatinib)
  • Flow cytometry to exclude lymphocytic variant HES
  • Serum tryptase and vitamin B12 (elevated in myeloproliferative variants)

Treatment Algorithm

For Confirmed Hypereosinophilic Syndrome with Hair Loss

Immediate corticosteroid therapy is first-line 1, 6:

  • Oral prednisone 1 mg/kg/day initially
  • Effective for reducing both hair loss and blood eosinophilia
  • Critical caveat: Relapse is common after discontinuation, requiring long-term maintenance 1

For Parasitic Infections

Empiric treatment while awaiting results in endemic-exposed patients 2:

  • Ivermectin 200 μg/kg daily for 2 days (Strongyloides)
  • Albendazole 400 mg twice daily for 3 days (Ascaris, hookworm)
  • Praziquantel 40 mg/kg single dose for Schistosomiasis

Critical warning for Loa loa: Do NOT use diethylcarbamazine if microfilariae seen on blood film—may cause fatal encephalopathy; use corticosteroids with albendazole first 2

For Myeloproliferative Variants

Imatinib 100-400 mg daily for FIP1L1-PDGFRA-positive cases 3

Common Pitfalls to Avoid

  • Do not assume allergy alone explains hypereosinophilia (≥1.5 × 10⁹/L)—this level is rarely if ever caused by allergy and demands full workup 5, 6
  • Do not rely on symptoms alone to assess organ damage—cardiac involvement can be subclinical initially 2
  • Do not assume normal eosinophil count excludes parasites—many helminth-infected patients have normal counts 2
  • Do not delay cardiac evaluation in moderate-to-severe eosinophilia—endomyocardial fibrosis can develop rapidly 3, 2
  • Do not start corticosteroids before excluding Strongyloides in at-risk patients—can precipitate fatal hyperinfection 2

Prognosis and Monitoring

For HES-related diffuse alopecia with massive perifollicular eosinophils 1:

  • Corticosteroids effectively reduce hair loss and eosinophilia
  • Immediate relapse typical after treatment cessation
  • Long-term maintenance therapy required
  • Regular monitoring of AEC and organ function essential

References

Guideline

Eosinophilia Evaluation and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Workup for eosinophilia.

Allergy and asthma proceedings, 2019

Research

Practical approach to the patient with hypereosinophilia.

The Journal of allergy and clinical immunology, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.